If you have been reading about alpha-MSH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
== Reactions == DBNPA decomposition is dominated by two reaction pathways: pH-dependent hydrolysis and light-catalyzed reactions with reducing nucleophiles. DBNPA's electrophilic bromine atoms and electron-withdrawing cyano (-CN) group play a major role in determining its reactivity. A number of variables, including temperature, pH, light exposure, and reducing agents, have a substantial impact on the rate and mechanism of DBNPA breakdown. Different organic and inorganic byproducts could therefore develop, which could have an impact on DBNPA's toxicity and biocidal effectiveness.
Someone with a good memory of the conversation once told me how Lord Carrington, then one of the "mediators" of the incipient post-Yugoslavia war, came to the conclusion that Slobodan Milosevic was a highly dangerous man. Well-disposed toward Serbia (as the British establishment has always been), Carrington told the late dictator that he understood Serb concerns about significant Serbian minorities in Bosnia and Croatia. But why did Milosevic also insist on exclusive control over Kosovo, where the Albanian population was approximately 90 percent? "That," replied Milosevic coldly, "is for historical reasons." It's a shame, in retrospect, that it took us so long to diagnose the pathology of Serbia's combination of arrogance and self-pity, in which what is theirs is theirs and what is anybody else's is negotiable. After the war, Hitchens supported Kosovo's independence and criticized the burning of the US Embassy in Belgrade as a response to it:
== History == Heparin was discovered by Jay McLean and William Henry Howell in 1916, although it did not enter clinical trials until 1935. It was originally isolated from dog liver cells, hence its name (ἧπαρ hēpar is Greek for 'liver'; hepar + -in). McLean was a second-year medical student at Johns Hopkins University, and was working under the guidance of Howell investigating pro-coagulant preparations when he isolated a fat-soluble phosphatide anticoagulant in canine liver tissue. In 1918, Howell coined the term 'heparin' for this type of fat-soluble anticoagulant. In the early 1920s, Howell isolated a water-soluble polysaccharide anticoagulant, which he also termed 'heparin', although it was different from the previously discovered phosphatide preparations. McLean's work as a surgeon probably changed the focus of the Howell group to look for anticoagulants, which eventually led to the polysaccharide discovery. It had at first been accepted that it was Howell who discovered heparin. However, in the 1940s, Jay McLean became unhappy that he had not received appropriate recognition for what he saw as his discovery. Though relatively discreet about his claim and not wanting to upset his former chief, he gave lectures and wrote letters claiming that the discovery was his. This gradually became accepted as fact, and indeed after he died in 1959, his obituary credited him as being the true discoverer of heparin.
Sources: en.wikipedia.org
Cone snails are prized for their brightly colored and patterned shells, which may tempt people to pick them up. This is risky, as the snail often fires its harpoon in self defense when disturbed. The harpoons of some of the larger species of cone snail can penetrate gloves or wetsuits. The sting of many of the smallest cone species may be no worse than a bee or hornet sting, but the sting of a few of the larger tropical fish-eating species, such as Conus geographus (geography cone), Conus tulipa and Conus striatus, can be fatal. Other dangerous species are Conus pennaceus, Conus textile, Conus aulicus, Conus magus and Conus marmoreus. According to Goldfrank's Toxicologic Emergencies, about 27 human deaths can be confidently attributed to cone snail envenomation, though the actual number is almost certainly much higher; some three dozen people are estimated to have died from geography cone envenomation alone. Most of the cone snails that hunt worms are not a risk to humans, with the exception of larger species. One of the fish-eating species, the geography cone, is also known colloquially as the "cigarette snail", a gallows humor exaggeration implying that, when stung by this creature, the victim will have only enough time to smoke a cigarette before dying. Symptoms of a more serious cone snail sting include severe, localized pain, swelling, numbness and tingling, and vomiting. Symptoms can start immediately or can be delayed for days. Severe cases involve muscle paralysis, changes in vision and respiratory failure that can lead to death.
Ukrainian officials criticized the move. In January 2021, Sputnik Light commenced phase I/II trials. In February, Sputnik Light commenced phase III trials. Effectiveness is generally expected to slowly decrease over time. A real-world study with participants aged 60–79 years in Argentina found that the single-injection vaccine is 79% (95% CI, 75–82%) effective in preventing infections, 88% (95% CI, 80–92%) effective against hospitalization, and 85% (95% CI, 75–91%) against death. A phase III clinical trial in Russia also found an efficacy of 79%. According to Nextstrain, lineage B.1.1.317 was the dominant variant in Russia during the study period (5 December 2020 to 15 April 2021), while in Argentina (29 December 2020 to 21 March 2021) lineage N.5 dominated at first, but soon many lineages coexisted in similar proportions. Preliminary data from a study in Moscow in July 2021 indicate that the vaccine is 70% (95% CI, 64–75%) effective against symptomatic disease from the Delta variant for three months after vaccination. In August 2021, RDIF announced that preliminary results from a study on heterologous prime-boost vaccination indicate that it is safe to administer Sputnik Light as the first dose, then the Oxford–AstraZeneca, Moderna or Sinopharm BIBP vaccine as the second dose, as well as the homologous course consisting of Sputnik Light as the second dose. On 11 August 2021, the developers of the Sputnik V vaccine offered its 'Sputnik Light' (Ad26) vaccine to Pfizer for trial against the Delta variant.
Morphine, or any salt of morphine, ester of morphine or salt of ester of morphine (§6, (2)); Diamorphine (heroin) or any salt of diamorphine (§6, (3)); Cocaine or any salt of cocaine (§6, (4)); Methamphetamine (§6, (5)). Under the Act:
Sources: en.wikipedia.org
Trump's second term foreign policy has been described as a mixture of both imperialist and expansionist policies. He engaged in a realist and isolationist "America First" foreign policy agenda. His administration favored hard power to achieve foreign policy goals, and dismantled or withdrew support from domestic and international organizations dedicated to advancing American soft power. The moves were described as ceding American global influence and creating a void filled by Russia and China. His relations with allies were transactional and ranged from indifference to hostility, and he threatened them with economic tariffs or annexation. He was described as taking the side of Russia in the Russian invasion of Ukraine, and overseeing a rupture of the post-1945 rules-based liberal international order and abandonment of multilateralism. Michael Klare wrote that containing the influence of China and preventing the rise of any rival power is the central foreign policy objective of the administration. Trump has attempted to deepen the U.S.-India partnership. Trump's administration saw large drops in global public opinion of the U.S. Countries like Canada, Germany, the U.K., Denmark, and Finland warned their citizens about traveling to the U.S.
== Awards and honors == In 2020, Flegg was awarded the JH Michell Medal for excellence in research by ANZIAM (Australian and New Zealand Industrial and Applied Mathematics), as well as the Christopher Heyde Medal from the Australian Academy of Science and the Society of Mathematical Biology. In 2025, Flegg was awarded the EO Tuck Medal by the Australian Mathematical Society in recognition of her outstanding research and distinguished service to the field of applied mathematics. She was elected a Fellow of the Australian Academy of Science in 2026.
=== Semi-chisel saw chains === The semi-chisel chain has teeth with rounded corners formed by a radius between the top and side plates. While slower than full chisel in softwood, it retains an acceptable cutting sharpness longer, making it the preferred choice for dirtier wood, hard or dry wood, frozen wood or stump work, all of which would rapidly degrade full chisel chain. They are similar to the full chisel design but have a small 45 degree chamfer between the plates rather than a radius. Performance is similar to full chisel. Semi chisel chains have a lower kick-back risk. These chains are available for consumer, semi-pro and professional saws.
Another reason for the gender gap is the fact that young women are better educated and earning more than men in the contemporary American economy. In all, American women below the age of 30 have been moving leftward on a number of key political issues while young men have not moved as much. There is little to no gap in terms of educational attainment or race. Meanwhile, a majority of Gen Z men are engaging with contents from "masculinity influencers" on the Internet, who promote traditional gender roles in which men make the decisions and women comply.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.